Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
 
  • Details

Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial

Journal
Gut
Journal Volume
64
Journal Issue
2
Pages
303-311
Date Issued
2015
Author(s)
CHEN-HUA LIU  
CHUN-JEN LIU  
Huang C.-F
JOU-WEI LIN  
Dai C.-Y
Liang C.-C
Huang J.-F
Hung P.-H
HUNG-BIN TSAI  
MENG-KUN TSAI  
CHIH-YUAN LEE  
Chen S.-I
Yang S.-S
TUNG-HUNG SU  
HUNG-CHIH YANG  
PEI-JER CHEN  
DING-SHINN CHEN  
Chuang W.-L
Yu M.-L
JIA-HORNG KAO  
DOI
10.1136/gutjnl-2014-307080
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84920999772&doi=10.1136%2fgutjnl-2014-307080&partnerID=40&md5=4f3189bd1469820c4207c437125fcf88
https://scholars.lib.ntu.edu.tw/handle/123456789/434606
Abstract
Objective: Data comparing the efficacy and safety of combination therapy with peginterferon plus low-dose ribavirin and peginterferon monotherapy in treatment-naive haemodialysis patients with hepatitis C virus genotype 2 (HCV-2) infection are limited. Design: In this randomised trial, 172 patients received 24 weeks of peginterferon alfa-2a 135 μg/week plus ribavirin 200 mg/day (n=86) or peginterferon alfa-2a 135 μg/week (n=86). The efficacy and safety endpoints were sustained virological response (SVR) rate and adverse event (AE)-related withdrawal rate. Results: Compared with monotherapy, combination therapy had a greater SVR rate (74% vs 44%, relative risk (RR): 1.68 [95% CI 1.29 to 2.20]; p<0.001). The beneficial effect of combination therapy was more pronounced in patients with baseline viral load ?800 000 IU/mL than those with baseline viral load <800 000 IU/mL (RR: 3.08 [95% CI 1.80 to 5.29] vs RR: 1.11 [95% CI 0.83 to 1.45]; interaction p=0.001). Patients receiving combination therapy were more likely to have a haemoglobin level of <8.5 g/dL (70% vs 8%, risk difference (RD): 62% [95% CI 50% to 73%]; p<0.001) and required a higher dosage [mean: 13 417vs 6667 IU/week, p=0.027] of epoetin β to manage anaemia than those receiving monotherapy. The AE-related withdrawal rates were 6% and 3% in combination therapy and monotherapy groups, respectively (RD: 2% [95% CI -4% to 9%]). Conclusions: In treatment-naive haemodialysis patients with HCV-2 infection, combination therapy with peginterferon plus low-dose ribavirin achieved a greater SVR rate than peginterferon monotherapy. Most haemodialysis patients can tolerate combination therapy.
SDGs

[SDGs]SDG3

Other Subjects
hemoglobin; peginterferon alpha2a; ribavirin; alpha interferon; antivirus agent; erythropoietin; hemoglobin; macrogol derivative; peginterferon alpha2a; recombinant erythropoietin; recombinant protein; ribavirin; adult; adverse outcome; alopecia; anemia; anorexia; Article; chronic kidney disease; comparative effectiveness; constipation; controlled study; coughing; depression; dermatitis; diarrhea; drug dose reduction; drug efficacy; drug safety; drug withdrawal; fatigue; female; flu like syndrome; follow up; hair loss; headache; hemodialysis; hepatitis C; Hepatitis C virus genotype 2 infection; Hepatitis C virus genotype 2 infection; human; injection site reaction; insomnia; major clinical study; male; medication compliance; monotherapy; multicenter study; neutropenia; outcome assessment; patient compliance; randomized controlled trial; thrombocytopenia; treatment response; virus load; aged; anemia; blood; chemically induced; clinical trial; dose response; drug combination; genetics; genotype; Hepacivirus; Hepatitis C, Chronic; isolation and purification; metabolism; middle aged; renal replacement therapy; treatment outcome; virology; young adult; Adult; Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Treatment Outcome; Viral Load; Young Adult
Publisher
BMJ Publishing Group
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science